Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 15/20 | 0.76 |
| ▸ | MMP13 | P45452 | 14/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 5/20 | 0.43 |
| ▸ | MMP2 | P08253 | 3/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691684 | 0.98 | MMP1 (0.79) | MMP1MMP13SMN1; SMN2MMP9MMP2 | |
| SCHEMBL6813262 | 0.92 | MMP1 (0.67) | MMP1MMP13SMN1; SMN2MMP9MMP2 | |
| SCHEMBL6813089 | 0.92 | MMP1 (0.67) | MMP1MMP13SMN1; SMN2MMP9MMP2 | |
| SCHEMBL3914707 | 0.92 | MMP1 (0.63) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6693057 | 0.90 | MMP1 (0.68) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6809653 | 0.90 | MMP1 (0.62) | MMP1MMP13SMN1; SMN2CETPLTA4H | |
| SCHEMBL6691163 | 0.89 | MMP1 (0.65) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6862342 | 0.89 | MMP1 (0.59) | MMP1MMP13SMN1; SMN2MMP9MMP2 | |
| SCHEMBL13556928 | 0.89 | MMP1 (0.81) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL25130 | 0.88 | MMP1 (0.96) | MMP1MMP13MMP9MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1003720-B1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2004-03-31 | — | — | EP | claimed |
| US-6417229-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-07-09 | — | — | US | claimed |
| US-6214872-B1 | ANTIARTHRITIC AND ANTICARCINOGENIC AGENTS | PFIZER INC. | 2001-04-10 | — | — | US | claimed |
| EP-1088550-A1 | alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| EP-1003720-A1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1999007675-A1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-02-18 | — | — | WO | claimed |
| EP-1068180-B1 | PROCESS FOR ALKYLATING HINDERED SULFONAMIDES USEFUL IN THE PRODUCTION OF MATRIX METALLOPROTENASE INHIBITORS | PFIZER PROD INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1415984-A1 | Aryloxyarylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1003720-B1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-0949246-B1 | Process for preparing phenoxyphenylsulfonyl halides | PFIZER PROD INC (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6417229-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-07-09 | — | — | US | disclosed |
| EP-0949245-B1 | Process for alkylating hindered sulfonamides | PFIZER PROD INC (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6288246-B1 | REACTION OF HYDROXYLAMINE WITH ALKYLSILYL HALIDE, HYDROLYSIS WITH ACID | PFIZER INC | 2001-09-11 | — | — | US | disclosed |
| US-6114568-A | Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors | PFIZER INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-1003720-A1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999052862-A1 | PROCESS FOR ALKYLATING HINDERED SULFONAMIDES USEFUL IN THE PRODUCTION OF MATRIX METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| EP-0949244-A2 | Process for preparing hydroxamic acids | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0949245-A1 | Process for alkylating hindered sulfonamides | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0949246-A1 | Process for preparing phenoxyphenylsulfonyl halides | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999007675-A1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-02-18 | — | — | WO | disclosed |